Observations on the Effects of Hematopoietic Colony-Stimulating Factors on the Clinical Course of Bone Marrow Transplantation
The use of the hematopoietic colony-stimulating factors (CSF) in clinical oncology and infectious disease has profound implications for the practice of medicine. The ability to influence the hematopoietic system with these factors offers the potential to reduce the morbidity and mortality associated with the use of chemotherapy, particularly intensive chemotherapy, and also to influence the outcome of various nonmalignant disorders of hematopoiesis.
KeywordsHematopoietic Progenitor Intensive Chemotherapy Autologous Bone Marrow Transplantation Hematopoietic Recovery Bone Marrow Support
Unable to display preview. Download preview PDF.
References Further Reading
- Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318: 869–876PubMedCrossRefGoogle Scholar
- Peters WP, Atwater S, Kurtzberg J, Borowitz M, Brandt SJ, Coleman RE, Kim CS, Gilbert C, Shpall EJ, Jones RB, Shogan J, Oette D, Stuart A, Coniglio D, Affronti ML, Evans S (1989a) The use of recombinant human granulocyte- macrophage colony-stimulating factor in autologous bone marrow transplantation. Bone marrow transplantation: current controversies. Liss, New York, pp 595–606Google Scholar
- Peters WP, Kurtzberg J, Kirkpatrick G, Atwater S, Gilbert C, Borowitz M, Shpall E, Jones R, Ross M, Affronti M, Coniglio D, Mathias B, Oette D (1989b) GM- CSF primed peripheral blood progenitor cells (PB PC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high dose chemotherapy (HDC). Blood 74: 178Google Scholar